BioReference Laboratories, Inc. (NASDAQ: BRLI) and its GenPath Oncology
business unit and through its exclusive commercialization agreement with
the Massachusetts General Hospital (MGH) is introducing its
groundbreaking solid tumor genotype test. The test - which will be
marketed as OnkoMatchTM - will
help oncologists match patients with cancer therapies tailored to a
particular genetic mutation driving the disease and potentially identify
additional patients who might qualify for clinical trials. Beginning on
January 23, 2012, OnkoMatchTM
will be available to community oncology practices and hospitals
nationally through GenPath, making cutting edge technology accessible to
patients around the country.
This is the first time a solid tumor genotyping test for cancer has been
available nationally, combining the clinical and scientific expertise of
Mass General with the efficiency, service and technical capabilities of
GenPath. "Historically there has been a disconnect between academic
research and the clinical options available to most patients. Through
our commercialization agreement with MGH we have collaborated in key
areas such as bioinformatics and clinical interpretation to increase
tumor genotyping access nationally for patients. As drug companies
continue to invest in personalized therapies, there is a need to
identify more patients who could benefit from these advancements as well
as bring hope to those who have simply run out of therapeutic options."
said Marc D. Grodman, MD, President and CEO of BioReference Laboratories.
OnkoMatchTM is specifically
designed for solid tumor cancers such as lung, breast, colon, pancreas,
thyroid and skin. From a single tissue specimen taken from the patient's
tumor, the test will analyze 14 oncogenes, genes that drive cancer,
across 68 mutational hot spots. "We used sophisticated DNA extraction
and mutational analysis techniques developed at MGH's Translational
Research Laboratory, based on a process called multiplex PCR"
(polymerase chain reaction) technology," said John Iafrate, MD-PhD,
Director of Molecular Pathology at Massachusetts General Hospital and
Associate Professor at Harvard Medical School. "We can now extract DNA
samples from extremely small tumor tissue samples, targeting many genes
at once and accurately reporting the mutations that are being tested."
Tumor genotyping through OnkoMatchTM
will enable oncologists to match their patients with appropriate
targeted therapy, either FDA approved or in a clinical trial setting.
Often patients with advanced disease are refractory to currently
approved therapies and as a result, investigational therapies are sought
to induce a tumor response. GenPath will share with the oncologist links
to clinical trials associated with detected mutations allowing them to
quickly access information needed to enroll patients in an appropriate
In comparison to other tumor genotyping assays, such as next-gen
sequencing, OnkoMatchTM is
significantly less costly (<$1,000) and reported much more quickly. The
turn-around time for OnkoMatchTM
is seven days - significantly faster than the standard 3-4 weeks for
genotyping tests. "OnkoMatchTM
represents a seismic shift in cancer diagnostics. The test will enable
oncologists to genetically profile a patient's tumor at a reasonable
cost thus increasing patient access to novel therapies." said Dr.
Grodman. OnkoMatchTM is expected
to be covered by all major insurance carriers.
"This kind of genotyping is going to become part of everyday care for
cancer patients, and we are enthusiastic that GenPath will make it
broadly available," noted Dr. Iafrate.
About BioReference Laboratories, Inc.
BRLI is a clinical testing laboratory offering testing, information and
related services to physician offices, clinics, hospitals, employers and
governmental units. We believe that we are the fourth largest
full-service laboratory in the United States and the largest independent
regional laboratory in the Northeastern market. BRLI offers a
comprehensive list of laboratory testing services utilized by healthcare
providers in the detection, diagnosis, evaluation, monitoring and
treatment of diseases. BRLI primarily focuses on esoteric testing,
molecular diagnostics, anatomical pathology, women's health and
correctional health care.
Statements included in this release that are not historical in nature
are intended to be, and are hereby identified as, "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements may be identified by
words such as "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates," "will" or words of similar meaning and include,
but are not limited to, statements about the expected future business
and financial performance of Bio-Reference Laboratories, Inc. and its
subsidiaries. Such statements involve known and unknown risks and
uncertainties that may cause the Company's actual results in future
periods to be materially different from any future performance suggested
herein. Risks and uncertainties that may affect the future results of
the Company include, but are not limited to, adverse results from
failure to comply with applicable laws and regulations governing our
business or government investigations, lawsuits or private actions, the
competitive environment, changes in government regulations, changing
relationships with customers, payers, suppliers and strategic partners
and other risks and uncertainties detailed from time to time in our
filings with the Securities and Exchange Commission. We undertake
no obligation to publicly update or review any forward-looking
information, whether as a result of new information, future developments
Bio-Reference Laboratories, Inc.
Tara Mackay, Investor Relations